Pneumonia

Inclusion Criteria

- Males and non-pregnant, non-lactating females with written informed consent, 20 years of age or older. 
 - Within 48 hours prior to the first study drug administration, all patients should have the pathogens identified with appropriate specimens (e.g., sputum, tracheal aspirate, bronchoalveolar lavage [BAL], protected brushing specimen [PBS]), or should have appropriate specimens highly likely to identify the pathogens sampled. (However, the patients with Legionellosis is enrolled when the test of Legionella antigen is positive.)
 - The following severe bacterial pneumonia meeting the diagnostic criteria of pneumonia or secondary infection of chronic respiratory disease 
 -- Severe pneumonia
 --- Community-acquired pneumonia: PORT score III, IV or V
 --- Hospital-acquired pneumonia [HAP]-Group B and with a low risk for multidrug-resistant pathogens
 --- Patients with [HAP]-Group A whose pathogen is suspected to be Pseudomonas aeruginosa
 --- Hospitalized patients with bacterial pneumonia with a poor response to other antimicrobials 
Note: The patients should be limited to CAP patients with PORT score III, IV or V and HAP patients with-Group A or B who don’t respond to or have a poor response to other antimicrobials over 3day’s treatment.2
 -- Secondary infection of chronic respiratory disease
 --- Patients who are hospitalized for the treatment of secondary infection of chronic respiratory disease
 --- Hospitalized patients with secondary infection of chronic respiratory disease with a poor response to other antimicrobials
Note: The patients should be limited to secondary infection of chronic respiratory disease patients who don’t respond to or have a poor response to other antimicrobials over 3day’s treatment.

Exclusion Criteria

- Creatinine clearance (Ccr) ≤ 30 mL/min or nephrotic syndrome
 - Patient with chronic treatment of immunosuppressive drug
 - Decompensated congestive heart failure
 - Subject who received more than 24 hours of an antibacterial drug for the current infection
 - Patient who requires Intensive Care Unit (ICU) management [In case subjects who don’t correspond to the severity for ICU management need to be admitted to ICU due to a circumstance of the site (e.g. shortage of hospital beds), those subjects shall not be excluded]
 - Patients with infections other than pneumonia or secondary infection of chronic pulmonary disease
 - Lung abscess, or empyema
 - Viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis
 - Known or suspected bacteremia secondary to Staphylococcus aureus
 - Known causative microorganisms other than indication (microorganisms) of the study drug, or positive in urinary antigen test of Streptococcus pneumonia
 - Infection that necessitates the use of a concomitant antibacterial agent in addition to study medication  [excluding subjects with concomitant use of long-term, low-dose macrolide for chronic respiratory diseases, sulbactam sodium/ampicillin sodium (Unasyn-S) and clindamycin (Dalacin-S)]
 - Known bronchial obstruction or a history of post-obstructive pneumonia
 - Known primary lung cancer